Table 1.
Odds ratio (OR) for rate of coverage of patients under different therapeutic regimens
| Patients already in treatment | New patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Covered patients | Covered patients | |||||||
| Regimen | n | % | OR | (95% CI) | n | % | OR | (95% CI) |
| Antihypertensive agents | ||||||||
| α-Blockers | 539 | 78 | 5.39 | 4.46, 6.52 | 5 | 14 | ND | |
| Combinations of 3 and more classes | 1579 | 65 | 2.8 | 2.55, 3.08 | 2 | 10 | 0.95 | 0, 4.54 |
| Different combinations (two classes) | 1888 | 58 | 2.07 | 1.91, 2.24 | 4 | 10 | ND | |
| Calcium channel blockers | 2822 | 57 | 2.03 | 1.89, 2.18 | 26 | 14 | ND | |
| Loop diuretics | 351 | 52 | 1.63 | 1.39, 1.91 | 4 | 7 | ND | |
| Angiotensin II receptor antagonists | 449 | 42 | 1.09 | 0.95, 1.24 | 11 | 18 | 1.88 | 0.84, 4.17 |
| ACE-inhibitors | 3729 | 40 | Ref* | 34 | 10 | Ref* | ||
| Thiazide-like diuretics | 398 | 35 | 0.83 | 0.63, 0.94 | 2 | 3 | ND | |
| β-Blockers | 988 | 35 | 0.81 | 0.74, 0.88 | 9 | 6 | 0.59 | 0.25, 1.32 |
| Lipid-lowering agents | ||||||||
| Combinations | 30 | 60 | 5.1 | 2.79, 9.37 | – | – | – | – |
| Statins | 1036 | 23 | Ref* | 36 | 12 | Ref* | ||
| Fibrates | 109 | 17 | 0.71 | 0.57, 0.88 | 1 | 2 | ND | |
| Bile acid sequestrants | 2 | 10 | 0.36 | 0.06, 1.59 | – | – | – | – |
| Oral hypoglycaemic agents | ||||||||
| Biguanides | 286 | 71 | 3.05 | 2.38, 3.92 | 8 | 30 | 3.3 | 0.88, 12.67 |
| Sulphonylureas | 569 | 67 | 2.53 | 2.10, 3.04 | 18 | 29 | ND | |
| Combinations | 554 | 45 | Ref* | 6 | 11 | Ref* | ||
| Nitrates | ||||||||
| Combinations | 68 | 69 | 3.35 | 2.11, 5.32 | 13 | 65 | ND | |
| Isosorbide | 288 | 57 | 2.02 | 1.63, 2.50 | 4 | 40 | 3.96 | 1.16, 13.96 |
| Nitroglycerin | 501 | 40 | Ref* | 15 | 32 | Ref* | ||
*
Within each therapeutic category, the most frequent regimen or combination therapy were considered as reference treatment.